Mark Barash, DO
Pulmonary Disease · Milwaukee, WINPI 1215355011
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (50.5%), consulting fees and travel and lodging — rather than concentrated in one kind of arrangement. Boehringer Ingelheim accounts for 91.3% of it on its own, with 6 other manufacturers making up the rest. Among pulmonary disease clinicians in WI with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 65 payments — averaging $800.46 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boehringer Ingelheim$48K
- Intuitive Surgical$4K
- United Therapeutics Corporation$503
- GSK$232
- Pulmonx Corporation$177
- Boston Scientific$42
- plus $22 from 1 others
Across 146 payments — averaging $3054.64 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- United Therapeutics Corporation$446K
What the payments were for
- Consulting fees$14,57328%
- Speaking & faculty fees$26,30051%
- Travel & lodging$5,70811%
- Food & beverage$2,9496%
- Education$2,5005%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boehringer Ingelheim | 44 | $47,514 |
| Intuitive Surgical | 7 | $3,540 |
| United Therapeutics Corporation | 6 | $503 |
| GSK | 3 | $232 |
| Pulmonx Corporation | 2 | $177 |
| Boston Scientific | 1 | $42 |
| Electromed, Inc. | 2 | $22 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- OFEV$4,972
- Da Vinci Surgical System$3,397
- TYVASO$284
- NUCALA$119
- STEEN Solution$110
- Pulmonx Endobronchial Valve EBV$106
How this compares
$52,030 in reported general payments places this provider in the 95th percentile of 247 pulmonary disease providers in Wisconsin.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OfevNintedanib Esylate | 54 | $718,786 |
| NucalaMepolizumab | 11 | $39,981 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 36 | $37,567 |
| Pirfenidone | 29 | $31,004 |
| DuleraMometasone/Formoterol | 26 | $14,213 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 20 | $12,783 |
| Advair HfaFluticasone Propion/Salmeterol | 21 | $9,764 |
| SymbicortBudesonide/Formoterol Fumarate | 25 | $6,989 |
| Incruse ElliptaUmeclidinium Bromide | 22 | $6,898 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 13 | $6,385 |
| Arnuity ElliptaFluticasone Furoate | 15 | $4,867 |
| Breo ElliptaFluticasone/Vilanterol | 11 | $4,090 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 19 | $3,893 |
| Mycophenolate Mofetil | 26 | $3,110 |
| Omeprazole | 56 | $1,675 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimOfev, Stiolto Respimat, Combivent Respimat | $47,514 | $737,95387 claims |
| GSKNucala, Trelegy Ellipta, Incruse Ellipta, Arnuity Ellipta, Breo Ellipta | $232 | $93,40295 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 247 pulmonary disease providers in Wisconsin.
Other pulmonary disease in Milwaukee
- Jonathan KurmanMilwaukee$803K
- Mouhammed RihawiMilwaukee$713K
- Kurt HuMilwaukee$55K
- Julie BillerMilwaukee$52K
- Rahul NanchalMilwaukee$42K
- Steven LehMilwaukee$40K
- Ali MusaniMilwaukee$38K
- Michael KatzoffMilwaukee$37K
- Uzair GhoriMilwaukee$32K
- Jayshil PatelMilwaukee$25K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.